Dave Gardner is the new Executive Vice President and Chief Strategy Officer (CSO) at Incyte.
In his new role, Mr. Gardner will serve on the Executive Leadership Team and be responsible for the Company’s strategy and business development.
“Dave possesses a unique combination of business acumen, scientific knowledge and deep industry experience. His extensive background in biopharma investing will bring a fresh perspective and a focused, judicious approach to corporate development,” says Bill Meury, President and Chief Executive Officer of Incyte, in a news release. “Dave will play a pivotal role in developing a coherent and executable long-term growth strategy for the company and ensuring our portfolio decisions, business development and strategic partnerships position Incyte for sustainable value creation.”
Mr. Gardner most recently served as Partner on the Therapeutics Team at Rock Springs Capital Management, leading strategy across Oncology, Neurology, Immunology and Rare Diseases. Prior to that, he spent a decade at BlackRock as Vice President and Equity Research Analyst where he was responsible for the Health Care sector.
After nine years as a member of the Incyte leadership team, Vijay Iyengar, MD, Executive Vice President and Head of Global Medical Affairs and Product and Partnership Strategy, will be retiring and continue to provide transitional support to Mr. Gardner through the end of the year.
